A listed company, a well-known over-the-counter OTC drug, a pharmaceutical company dedicated to the research of orlistat preparation series products, integrating the R&D and production of APIs and preparations

In 2011, with the approval of the China Food and Drug Administration, Hisun Pharmaceutical officially launched the over-the-counter OTC drug Yiningman orlistat.

Founded in 1956, Hisun Pharmaceutical Co., Ltd. is a state-controlled listed company, headquartered in Taizhou City, Zhejiang Province, with more than 9,000 employees, and is a comprehensive and global pharmaceutical enterprise integrating R&D and production of APIs and preparations, with business in more than 70 countries and regions around the world.

As one of the first batch of innovative enterprises in China, Hisun has established a state-recognized enterprise technology center, a postdoctoral research workstation and an academician workstation. It has six research institutes of chemical drugs, microbial drugs, and biological drugs, as well as drug screening, strain identification and preservation, instrumental analysis, information center, EHS analysis and other centers.

Hisun Pharmaceutical is one of the world's leading suppliers of orlistat APIs. At present, Hisun actively promotes the innovation and internationalization of national medicine, and continuously promotes the integration of raw materials, the branding and bio-industrialization of Hisun's raw materials, and develops from a single API export to the synchronization of APIs and self-owned brand preparations.

Focusing on the two major fields of "biological drugs and chemical drugs", Hisun has developed its own brand of new drugs, and has formed characteristics and advantages in the industrialization of characteristic APIs and high-end preparations.